Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Endo Pharmaceuticals Inc history
Endo Pharmaceuticals Inc company history timeline
Management Team Launch of Endo Pharmaceuticals in 1997
1997: A management team acquires the DuPont Merck pain management drugs and the Endo name.
Endo posted a net profit of $201,000 in 1998, then a year later saw sales increase 28 percent to $138 million and net income to $3.26 million.
During 1998 talks, Endo shared its plans to develop a new Percocet product, one that included Tylenol's active ingredient, acetaminophen.
In November 1999 it reached an agreement to acquire Algos Pharmaceutical Corporation, a New Jersey-based biotech company that also specialized in pain management products.
Hind then developed a 5 percent lidocaine solution hand-sized patch, which gained FDA approval and which Endo began marketing as Lidoderm in 1999.
In October 2000, The Purdue Frederick Company sued Endo, alleging that Endo had infringed on patents relating to OxyContin by developing a generic form of the drug.
Sales grew another 43 percent in 2000 to $187.4 million.
2000: Endo becomes a public company by acquiring Algos Pharmaceutical Corporation.
In early 2001 Endo sued Watson Pharmaceuticals Inc., a California generic-drug maker with whom it had considered forming an alliance.
Endo increased sales to $252 million in 2001, due to the launch of new strengths of Percocet and the strong growth of Lidoderm.
Launched in the United States in June 2002.
The company suffered a setback in 2002 when MorphiDex failed to demonstrate in a late-stage clinical trial that it performed better than simple morphine in relieving pain.
In 2003 Endo added a pair of painkillers, paying $120 million to British biotech SkyePharma for the rights to Depomorphine and Propofol IDD-D, along with options on other products.
In 2004 Endo launched a pair of branded drugs: Frova and DepoDur, and along with continued strong growth in Lidoderm, the company was able to increase sales to $615.1 million.
On March 23, 2009, Endo Pharmaceuticals successfully completed its acquisition of Indevus Pharmaceuticals, Inc.
On November 4, 2010, Penwest Pharmaceuticals becomes a wholly owned subsidiary of Endo Pharmaceuticals.
On January 28, 2011, Endo enters into a collaboration agreement with Orion Corporation for the discovery, development and commercialization of assets in Oncology.
On March 3, 2011, Endo Launches FORTESTA® (Testosterone) Gel.
On June 20, 2011, American Medical Systems Inc (AMS) becomes a wholly owned subsidiary of Endo Pharmaceuticals.
In February 2012, Endo announces the aggregation of its operating companies as part of an enterprise-wide branding initiative; announces corporate name change to Endo Health Solutions.
December 2012, Endo’s board announces the retirement of President and CEO Dave Holveck.
In June 2013, Endo announces strategic change to focus on providing quality healthcare products through distinct operating companies, and announces restructuring to improve operating margins.
On February 3, 2014, Endo completed its divestiture of HealthTronics to Altaris Capital Partners, LLC.
On February 10, 2015, Endo completes acquisition of Litha Healthcare Group.
On February 29, 2016, Endo announces the wind down of ASTORA Women’s Health Business (formerly AMS Women’s Health).
On September 27, 2016, Endo names Paul V. Campanelli President, Chief Executive Officer and a Director of Endo.
On February 28, 2017, Endo announces strategic change to unify its operating model, enhance the generics pipeline through investment in hard-to-produce assets & technologies, transform the branded business into a highly focused Specialty business and divest non-core assets.
On October 25, 2017, Endo completes its divestiture of Grupo Farmacéutico SOMAR to Advent International.
In July 2018, Endo establishes Nevakar Licensing Agreement, development of 5 differentiated, 505(b)(2) sterile injectable products.
On November 7, 2018, Endo announces positive results from Phase 3 studies of collagenase clostridium histolyticum (CCH) in patients with cellulite.
On July 31, 2019, Endo and Helsinn announce agreement for Paladin Labs to commercialize Pracinostat in Canada.
On November 4, 2019, Endo names Paul V. Campanelli Chairman, President and Chief Executive Officer of Endo.
On December 10, 2019, Endo begins shipment of the first generic version of Novartis’ Afinitor® (everolimus) 2.5 mg, 5 mg and 7.5 mg tablets.
On January 27, 2020, Endo begins shipment of an authorized generic version of Allergan’s Carafate® (sucralfate) oral suspension 1gm/10 mL.
On March 6, 2020, Blaise Coleman becomes President and Chief Executive Officer of Endo.
On July 6, 2020, Endo announces that it received FDA approval of Qwo® (collagenase clostridium histolyticum-aaes).
On September 25, 2020, Endo announces a non-exclusive agreement with Novavax, Inc. to provide fill-finish manufacturing services for Novavax’s COVID-19 vaccine candidate.
On December 2, 2020, Endo completes acquisition of BioSpecifics Technologies Corp.
Rate how well Endo Pharmaceuticals Inc lives up to its initial vision.
Endo Pharmaceuticals Inc jobs
Do you work at Endo Pharmaceuticals Inc?
Does Endo Pharmaceuticals Inc communicate its history to new hires?
Endo Pharmaceuticals Inc competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Warner Chilcott | 1968 | $105.1M | 3,000 | - |
| Daiichi Sankyo | 2005 | $9.0B | 15,348 | 50 |
| PDI | 1987 | $22.0M | 350 | 32 |
| Janssen | 1953 | $601.4M | 1,500 | 3 |
| Organon | - | $6.4B | 158 | 138 |
| Depomed | 1995 | $342.7M | 494 | - |
| Forest Pharmaceuticals Inc | 1954 | $40.0M | 50 | - |
| Eisai | 1995 | $5.3B | 1,864 | 143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1998 | $12.1B | 30,481 | 1,340 |
| Sanofi US | 1973 | $980.0M | 110,000 | 768 |
Endo Pharmaceuticals Inc history FAQs
Zippia gives an in-depth look into the details of Endo Pharmaceuticals Inc, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Endo Pharmaceuticals Inc. The employee data is based on information from people who have self-reported their past or current employments at Endo Pharmaceuticals Inc. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Endo Pharmaceuticals Inc. The data presented on this page does not represent the view of Endo Pharmaceuticals Inc and its employees or that of Zippia.
Endo Pharmaceuticals Inc may also be known as or be related to ENDO HEALTH SOLUTIONS INC., Endo Health Solutions Inc, Endo Health Solutions Inc., Endo International plc, Endo Pharmaceuticals and Endo Pharmaceuticals Inc.